Mental disorders in patients with cystic fibrosis

   Introduction. Cystic fibrosis (CF) is a genetic disease that leads to dysfunction of internal organs and significantly increases the risk of respiratory infections. According to the N. P. Bochkov Medical and Genetic Research Center, 1 out of 9,000 newborns suffers from CF. Chronic disease has a negative impact on mental health and can contribute to the development
of anxiety and depressive disorders, as well as accentuated traits and personality disorders.

   Aim. To summarize the currently available data on mental disorders in patients with CF, as well as to summarize current recommendations regarding the management of patients with this disease.

   Materials and methods. Articles were searched in Google Scholar databases, eLIBRARY.ru, Elsevier, PubMed from 2014 to 2024 by key words in Russian and English in accordance with the purpose of the study.

   Results. It has been established that mental health problems are associated with worse compliance to the treatment, as well as difficulties with self-organization and self-care. Some hypotheses that explain the pathogenesis of mental disorders have been provided. The key characteristics of course and clinical presentation of mental disorders in this group of patients have been described. Some potential recommendations for the treatment are provided, taking into the account the specificities of the metabolism of psychotropic drugs in people with CF. The tactics of management, including the creation of a multidisciplinary team that would consist of a doctor of somatic profile, psychiatrist and a psychologist. A strategy for development of this aspect of medical care for patients with CF has also been proposed.

   Conclusion. Drawing the attention of the scientific community to the problem of mental disorders in patients with CF will allow the introduction of methods for monitoring mental status and early detection of symptoms, and will also entail the creation of multidisciplinary teams, including a psychiatrist and a medical psychologist.

1. Quittner A.L., Abbott J., Georgiopoulos A.M. et al. International Committee on Mental Health; EPOS Trial Study Group. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax 2016;71(1):26–34. DOI: 10.1136/thoraxjnl-2015-207488

2. VanElzakker M.B., Tillman E.M., Yonker L.M. et al. Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort. Curr Opin Pulm Med 2023;29(6):603–9. DOI: 10.1097/MCP.0000000000001014

3. Elgudin L., Kishan S., Howe D. Depression in children and adolescent with cystic fibrosis: case studies. Int J Psychiatry Med 2004;34(4):391–7. DOI: 10.2190/N7DL-L6PE-MKYH-4910

4. Nieddu E. Cystic fibrosis: CFTR modulators and their mechanism of action. Curr Pharm Des 2013;19(19):3474–5. DOI: 10.2174/13816128113199990322

5. The register of patients with cystic fibrosis in the Russian Federation for 2021. Edited by S.A. Krasovsky, M.A. Starikova, A.Y. Voronkova еt al. St. Petersburg: Charitable Foundation “Islands”, 2023. (In Russ.).

6. Schechter M.S., Ostrenga J.S., Fink A.K. et al. Decreased survival in cystic fibrosis patients with a positive screen for depression. J Cyst Fibros 2021;20(1):120–6. DOI: 10.1016/j.jcf.2020.07.020

7. Amerio A., Sibilla F., Pescini R. et al. Mental health and cystic fibrosis: time to move from secondary prevention to predictive medicine. Pediatr Pulmonol 2020;55(9):2204–6. DOI: 10.1002/ppul.24928

8. Fidika A., Herle M., Goldbeck L. Symptoms of depression impact the course of lung function in adolescents and adults with cystic fibrosis. BMC Pulm Med 2014;14:205. DOI: 10.1186/1471-2466-14-205

9. Cystic Fibrosis Foundation Patient Registry. Annual data report 2021. Bethesda, Maryland. Available at: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf

10. Quittner A.L., Goldbeck L., Abbot J. et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax 2014;69(12):1090–7. DOI: 10.1136/thoraxjnl-2014-205983

11. Pearson D.A., Pumariega A.J., Seilheimer D.K. The development of psychiatric symptomatology in patients with cystic fibrosis. J Am Acad Child Adolesc Psychiatry 1991;30(2):290–7. DOI: 10.1097/00004583-199103000-00019

12. Bathgate C.J., Hjelm M., Filigno S.S. et al. Management of mental health in cystic fibrosis. Clin Chest Med 2022;43(4):791–810. DOI: 10.1016/j.ccm.2022.06.014

13. Talwalkar J.S., Koff J.L., Lee H.B. et al. Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis. Psychosomatics 2017;58(4):343–54. DOI: 10.1016/j.psym.2017.04.001

14. Bathgate C.J., Muther E., Georgiopoulos A.M. et al. Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers’ observations across US centers. Pediatr Pulmonol 2023;58(9):2469–77. DOI: 10.1002/ppul.26527

15. Dagenais R.V.E., Su V.C.H., Quon B.S. Real-world safety of CFTR modulators in the treatment of cystic fibrosis : a systematic review. J Clin Med 2020;10(1):23. DOI: 10.3390/jcm10010023

16. Heo S., Young D. C., Safirstein J. et al. Mental status changes during elexacaftor/tezacaftor/ivacaftor therapy. J Cyst Fibros 2022;21(2):339–43. DOI: 10.1016/j.jcf.2021.10.002

17. McKinzie C.J., Goralski J.L., Noah T.L. et al. Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis. J Cyst Fibros 2017;16(4):525–7. DOI: 10.1016/j.jcf.2017.05.008

18. Piehler L., Thalemann R., Lehmann C. et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis. Front Pharmacol 2023;14(1):1179208. DOI: 10.3389/fphar.2023.1179208

19. Baroud E., Chaudhary N., Georgiopoulos A.M. Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor. Pediatr Pulmonol 2023;58(7):1920–30. DOI: 10.1002/ppul.26412

20. Reyes-Martinez S., Segura-Real L., Gomez-Garcia A.P. et al. Neuroinflammation, microbiota-gut-brain axis, and depression: the vicious circle. J Integr Neurosci 2023;22(3):65. DOI: 10.31083/j.jin2203065

21. Yaltonskiy V.M., Abrosimov I.N. Coping behavior in adults with cystic fibrosis. Nacional’nyj psihologicheskij zhurnal = National Journal of Psychology 2014;(3):60–5. (In Russ.). DOI: 10.11621/npj.2014.0307

22. Arslan M., Chalmers S., Rentfrow K. et al. Suicide attempts in adolescents with cystic fibrosis on Elexacaftor / Tezacaftor / Ivacaftor therapy. J Cyst Fibros 2023;22(3):427–30. DOI: 10.1016/j.jcf.2023.01.015

23. Akiskal H.S., Mallya G. Criteria for the “soft” bipolar spectrum: treatment implications. Psychopharmacol Bull 1987;23(1):68–73. DOI: 10.3928/0048-5713-19861101-15

24. Akiskal K.K., Akiskal H.S. The theoretical underpinnings of affective temperaments: implications for evolutionary foundations of bipolar disorder and human nature. J Affect Disord 2005;85(1–2):231–9. DOI: 10.1016/j.jad.2004.08.002

25. Serafini G., Geoffroy P.A., Aguglia A. et al. Irritable temperament and lifetime psychotic symptoms as predictors of anxiety symptoms in bipolar disorder. Nord J Psychiatry 2018;72(1):63–71. DOI: 10.1080/08039488.2017.1385851

26. Amerio A., Magnani L., Castellani C. et al. The expression of affective temperaments in cystic fibrosis patients: psychopathological associations and possible neurobiological mechanisms. Brain Sci 2023;13(4):619. DOI: 10.3390/brainsci13040619

27. Vazquez G.H., Tondo L., Mazzarini L. et al. Affective temperaments in general population : a review and combined analysis from national studies. J Affect Disord 2012;139(1):18–22. DOI: 10.1016/j.jad.2011.06.032

28. Niehammer U., Straßburg S., Sutharsan S. et al. How personality influences health outcomes and quality of life in adult patients with cystic fibrosis. BMC Pulm Med 2023;23(1):190. DOI: 10.1186/s12890-023-02463-y

29. Abrosimov I.N. Coping with a chronic illness as a predictor of psychological adaptation. Lichnost’ v menyayushchemsya mire: zdorov’e, adaptaciya, razvitie. Personality in a changing world: health, adaptation, development 2020;8(2):192–200. (In Russ.). DOI: 10.23888/humj20202192-200

30. Darukhanavala A., Merjaneh L., Mason K. et al. Eating disorders and body image in cystic fibrosis. J Clin Transl Endocrinol 2021;26(100280):1–8. DOI: 10.1016/j.jcte.2021.100280

31. Bryon M., Shearer J., Davies H. Eating disorders and disturbance in children and adolescents with cystic fibrosis. Children’s Health Care 2008;37(1);67–77. DOI: 10.1080/02739610701766909

32. Petropoulou A., Bakounaki G., Grammatikopoulou M.G. et al. Eating disorders and disordered eating behaviors in cystic fibrosis: a neglected issue. Children (Basel) 2022;9(6):915. DOI: 10.3390/children9060915

33. Bailey J., Krick S., Fontaine K.R. The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity. Nutrients 2022;14(6);1216. DOI: 10.3390/nu14061216

34. Power H.A., Shivak S.M., Kim J. et al. A systematic review of attention-deficit / hyperactivity disorder in people living with cystic fibrosis. Pediatr Pulmonol 2024;59(4):825–33. DOI: 10.1002/ppul.26843.10.1002/ppul.26843

35. Cohen-Cymberknoh M., Dimand I., Tanny T. et al. The association between Attention-Deficit-Hyperactivity-Disorder (ADHD) symptoms and disease severity in people with Cystic Fibrosis (pwCF). J Cyst Fibros 2023;22(4):772–6. DOI: 10.1016/j.jcf.2023.04.004

36. Molitor S.J., Fidler A.L., Sinisterra M. et al. Associations between symptoms of ADHD/ODD and health outcomes in youth with cystic fibrosis. Pediatr Pulmonol 2024;59(3):809–12. DOI: 10.1002/ppul.26811

37. Vaziri S., McGarry M.E., Huang C.Y. et al. Time to be blunt: substance use in cystic fibrosis. Pediatr Pulmonol 2024;59(4): 1015–27. DOI: 10.1002/ppul.26880.10.1002/ppul.26880

38. Richards C.J., Friedman D., Pinsky H. et al. Alcohol and opiate misuse in adults with cystic fibrosis. Pediatr Pulmonol 2023;58(9):2535–42. DOI: 10.1002/ppul.26541

39. Lowery E.M., Afshar M., West N. et al. Self-reported alcohol use in the cystic fibrosis community. J Cyst Fibros 2020;19(1):84–90. DOI: 10.1016/j.jcf.2019.06.004

40. Maléth J., Balázs A., Pallagi P. et al. Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis. Gastroenterology 2015;148(2):427–39. DOI: 10.1053/j.gastro.2014.11.002

41. Villarreal-Zegarra D., Barrera-Begazo J., Otazu-Alfaro S. et al. Sensitivity and specificity of the Patient Health Questionnaire (PHQ-9, PHQ-8, PHQ-2) and General Anxiety Disorder scale (GAD-7, GAD-2) for depression and anxiety diagnosis: a cross-sectional study in a Peruvian hospital population. BMJ Open 2023;13(9):e076193. DOI: 10.1136/bmjopen-2023-076193